Finerenone and Kidney Outcomes in Patients With Heart Failure
In FINEARTS-HF, a population at low risk of adverse kidney outcomes, finerenone did not significantly modify the kidney composite outcomes. Finerenone led to a greater reduction in initial eGFR, but did not result in a significant difference in chronic eGFR slope vs placebo. Finerenone led to early and sustained reductions in albuminuria and reduced the risk of new-onset micro- and macroalbuminuria. (FINEARTS-HF [Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenon on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants with Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%]; NCT04435626).
Authors
- Sanjiv J. Shah (ORCID: https://orcid.org/0000-0002-5655-8201)
- Brian Lee Claggett (ORCID: https://orcid.org/0000-0002-4215-9218)
- Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
- Finnian R. Mc Causland (ORCID: https://orcid.org/0000-0002-0299-0533)
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Alasdair Henderson (ORCID: https://orcid.org/0000-0002-8903-4906)
- Faiez M. Zannad (ORCID: https://orcid.org/0000-0001-7456-1570)
- Bertram Pitt (ORCID: https://orcid.org/0000-0001-5880-275X)
- Patrick Schloemer (ORCID: https://orcid.org/0009-0004-7787-5662)
- Meike Brinker (ORCID: https://orcid.org/0000-0002-1560-9535)
- Scott David Solomon (ORCID: https://orcid.org/0000-0003-3698-9597)
- Michele Senni (ORCID: https://orcid.org/0000-0001-5502-7882)
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- Robert Perkins
- Ian J. Kulac (ORCID: https://orcid.org/0000-0002-0710-1088)
- Carolyn S.P. Lam (ORCID: https://orcid.org/0000-0003-1903-0018)
- Adriaan A. Voors (ORCID: https://orcid.org/0000-0002-5417-4415)
- Akshay S. Desai
- Markus F. Scheerer
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Bayer (United States) (US)
- National University of Singapore (SG)
- University of Groningen (NL)
- University of Michigan (US)
- Ospedale Papa Giovanni XXIII (IT)
- National University Heart Centre Singapore (SG)
- National Heart Centre Singapore (SG)
- University of Milano-Bicocca (IT)
- Bayer (Germany) (DE)
- University of Glasgow (GB)
- Université de Lorraine (FR)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1016/j.jacc.2024.10.091
- Citations
- 54
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 21.71
Funders
- Amgen
- AstraZeneca
- Bayer
- Satellite Healthcare
- American Regent
- National Institute of Diabetes and Digestive and Kidney Diseases